Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone.
Stress and anxiety are mainly regulated by amygdala and hypothalamic circuitries involving several neurotransmitter systems and providing physiological responses to peripheral organs via the hypothalamic-pituitary-adrenal axis and other pathways. The role of endogenous opioid peptides in this process is largely unknown. Here we show for the first time that anxiolytic parameters of explorative behavior in mice lacking prodynorphin were increased 2-4-fold in the open field, the elevated plus maze and the light-dark test. Consistent with this, treatment of wild-type mice with selective kappa-opioid receptor antagonists GNTI or norbinaltorphimine showed the same effects. Furthermore, treatment of prodynorphin knockout animals with U-50488H, a selective kappa-opioid receptor agonist, fully reversed their anxiolytic phenotype. These behavioral data are supported by an approximal 30% reduction in corticotropin-releasing hormone (CRH) mRNA expression in the hypothalamic paraventricular nucleus and central amygdala and an accompanying 30-40% decrease in corticosterone serum levels in prodynorphin knockout mice. Although stress-induced increases in corticosterone levels were attenuated in prodynorphin knockout mice, they were associated with minor increases in depression-like behavior in the tail suspension and forced swim tests. Taken together, our data suggest a pronounced impact of endogenous prodynorphin-derived peptides on anxiety, but not stress coping ability and that these effects are mediated via kappa-opioid receptors. The delay in the behavioral response to kappa-opioid receptor agonists and antagonist treatment suggests an indirect control level for the action of dynorphin, probably by modulating the expression of CRH or neuropeptide Y, and subsequently influencing behavior.
Wittmann
Walter
W
Department of Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
Schunk
Eduard
E
Rosskothen
Iris
I
Gaburro
Stefano
S
Singewald
Nicolas
N
Herzog
Herbert
H
Schwarzer
Christoph
C
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology; D000679:Amygdala / Q000378:metabolism; D000818:Animals; D001007:Anxiety / Q000378:metabolism* / Q000503:physiopathology; D001933:Brain Stem / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D004399:Dynorphins / Q000502:physiology; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D005106:Exploratory Behavior; D005260:Female; D006146:Guanidines; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D018782:Maze Learning; D008636:Mesencephalon / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout / Q000378:metabolism; D009019:Morphinans; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009478:Neuropeptide Y / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism*; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D011903:Raphe Nuclei / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors; D013315:Stress, Psychological / Q000503:physiopathology
C411465:17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan; D004745:Enkephalins; D006146:Guanidines; D009019:Morphinans; D009478:Neuropeptide Y; D009479:Neuropeptides; D011498:Protein Precursors; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D004399:Dynorphins; D003346:Corticotropin-Releasing Hormone; C033660:preproenkephalin; D003345:Corticosterone
Neuroreport. 1999 Nov 8;10(16):3399-403
10599852
Br J Pharmacol. 1997 Oct;122(3):520-4
9351509
Nat Genet. 2000 Apr;24(4):403-9
10742107
Nat Genet. 2000 Apr;24(4):410-4
10742108
Mol Pharmacol. 1998 Jan;53(1):6-13
9443927
Nat Genet. 1998 Jun;19(2):162-6
9620773
Neuron. 1998 Jun;20(6):1093-102
9655498
Brain Res. 1999 Jul 17;835(1):18-26
10448192
Brain. 2006 Mar;129(Pt 3):642-54
16399805
Neuropsychopharmacology. 2006 Apr;31(4):739-50
16123756
Neuropeptides. 2006 Apr;40(2):115-23
16439015
Peptides. 2006 Aug;27(8):2005-11
16774797
Brain Res. 2006 Aug 2;1102(1):135-44
16806114
Neuropsychopharmacology. 2006 Sep;31(9):1928-37
16292317
Amino Acids. 2006 Oct;31(3):251-72
16820980
Brain. 2007 Apr;130(Pt 4):1017-28
17347252
J Comp Neurol. 2007 Oct 20;504(6):702-15
17722034
J Pharmacol Exp Ther. 2007 Dec;323(3):838-45
17823306
Psychopharmacology (Berl). 2008 Jan;195(4):547-57
17891380
Behav Brain Res. 2008 Feb 11;187(1):67-71
17923159
J Neurosci. 2008 Jan 9;28(2):407-14
18184783
Psychoneuroendocrinology. 2008 May;33(4):425-36
18280051
Nat Genet. 2000 Apr;24(4):415-9
10742109
Brain Res. 2000 Apr 10;861(2):288-95
10760490
Eur J Pharmacol. 2000 May 12;396(1):49-52
10822054
Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):70-5
11165373
J Neurosci. 2001 Mar 1;21(5):1779-86
11222667
Brain Res. 2001 Aug 3;909(1-2):75-80
11478923
Neurosci Biobehav Rev. 2002 May;26(3):259-83
12034130
Psychopharmacology (Berl). 2002 Oct;163(3-4):467-76
12373447
Diabetes. 2002 Dec;51(12):3420-7
12453895
Eur J Pharmacol. 2003 Feb 28;463(1-3):117-32
12600705
Int Clin Psychopharmacol. 2003 Jul;18(4):191-202
12817153
J Neurosci. 2003 Jul 2;23(13):5674-83
12843270
Exp Toxicol Pathol. 2003 Jul;55(1):69-83
12940631
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4280-5
15024126
Life Sci. 2004 Jun 4;75(3):257-70
15135648
Neuropeptides. 2004 Aug;38(4):225-34
15337374
Peptides. 2004 Aug;25(8):1355-63
15350704
Dis Nerv Syst. 1970 Nov;31:Suppl:34-7
5312689
Mt Sinai J Med. 1974 Sep-Oct;41(5):615-25
4547223
Psychopharmacol Bull. 1987;23(1):145-9
3110855
Science. 1993 Jan 22;259(5094):528-31
8380941
Trends Neurosci. 1994 Feb;17(2):80-5
7512773
Ann N Y Acad Sci. 1996 Mar 22;780:36-48
8602738
Eur J Pharmacol. 1996 Jun 20;307(1):7-14
8831097
Gen Pharmacol. 1996 Jun;27(4):673-7
8853304
Physiol Behav. 1996 Oct;60(4):1183-6
8884951
Brain Res. 2000 Feb 28;857(1-2):283-5
10700578